Table 1.
Characteristics of study patients at baseline
| Characteristic | Etelcalcetide |
Control | |
|---|---|---|---|
| Etelcalcetide + Vit D | Etelcalcetide + Ca | ||
| Number of patients | 41 | 41 | 42 |
| Age, years, mean (SD) | 66.5 (11.6) | 66.8 (14.1) | 66.4 (10.5) |
| Men, n (%) | 32 (78.0) | 27 (65.9) | 25 (59.5) |
| Dialysis vintage, years, median (IQR) | 7.0 (2.3–13.6) | 5.8 (2.4–9.5) | 5.8 (2.4–12.0) |
| Underlying kidney disease, n (%) | |||
| Diabetes mellitus | 16 (39.0%) | 12 (29.3%) | 21 (50.0%) |
| Nephrosclerosis | 8 (19.5%) | 9 (22.0%) | 4 (9.5%) |
| Glomerulonephritis | 10 (24.4%) | 9 (22.0%) | 9 (21.4%) |
| Polycystic kidney disease | 1 (2.4%) | 0 (0.0%) | 2 (4.8%) |
| Unknown/other | 6 (14.6%) | 11 (26.8%) | 6 (14.3%) |
| Dialysis modality, n (%) | |||
| Hemodiafiltration | 17 (41.4%) | 16 (39.0%) | 18 (42.9%) |
| Hemodialysis | 24 (58.5%) | 25 (61.0%) | 24 (57.1%) |
| History of cinacalcet use, n (%) | 6 (14.6%) | 6 (14.6%) | 10 (23.8%) |
| History of parathyroidectomy, n (%) | 0 (0.0%) | 1 (2.4%) | 1 (2.4%) |
| Use of phosphate binders, n (%) | |||
| Oral calcium carbonate | 21 (51.2%) | 14 (34.1%) | 14 (34.1%) |
| Non–calcium-containing phosphate binders | 32 (78.0%) | 29 (70.7%) | 32 (78.0%) |
| Intact parathyroid hormone, pg/mL | |||
| Median (IQR) | 258 (223.5–336) | 266 (195.5–368.5) | 286 (212–357) |
| Mean (SD) | 284.3 (109.6) | 293.7 (138.5) | 311.3 (136.1) |
| Ca (albumin-corrected), mg/dL, mean (SD) | 9.2 (0.6) | 9.3 (0.7) | 9.2 (0.4) |
| Phosphate, mg/dL, mean (SD) | 5.1 (1.2) | 5.7 (1.7) | 5.4 (0.9) |
| BAP, μg/L, mean (SD) | 16.8 (9.2) | 22.0 (18.2) | 18.7 (9.1) |
| TRACP-5b, mU/dL, mean (SD) | 697.6 (404.4) | 800.3 (658.2) | 690.9 (326.5) |
BAP, bone-specific alkaline phosphatase; IQR, interquartile range; SD, standard deviation; TRACP-5b, tartrate-resistant acid phosphatase 5b; Vit D, vitamin D.
Dialysate calcium = 3 mEq/L.